Revelation Biosciences, Inc.
REVB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.86 | 0.02 | -0.07 |
| FCF Yield | -483.21% | -70.72% | -104.27% | -11.15% |
| EV / EBITDA | 0.34 | 0.20 | -0.51 | -8.33 |
| Quality | ||||
| ROIC | -169.38% | -130.23% | -1,032.35% | 18,115.39% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.22 | 60.59 | 1.04 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -151.71% | 35.06% | 0.03% | -5,117.99% |
| Safety | ||||
| Net Debt / EBITDA | 0.82 | 1.39 | 0.48 | 0.11 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -286.17 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -10,243.23 | -19,815.67 | -5,056.11 | -3,146.56 |